Misonix/Focus Surgery take Sonoblate to Europe:
This article was originally published in Clinica
Executive Summary
Misonix is to distribute Focus Surgery's Sonoblate 500 high frequency ultrasound (HIFU) system in Europe and Russia for the treatment of prostate cancer and other prostate conditions. Farmingdale, New York-based Misonix has signed a two-year deal with Indianapolis, Indiana-based Focus Surgery, in which it holds a 20% stake. The arrangement will be renewable yearly depending on minimum purchases. The CE-marked device will be marketed by Misonix's new sales force. Misonix "will benefit not only from manufacturing the product but [will] also participate in the mark-up to the end customer upon final sale", said president and CEO Michael McManus.